Conatus Pharmaceuticals Inc (CNAT.OQ) Quote| Reuters.com
Edition:
United States

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

2.04USD
24 Jun 2016
Change (% chg)

$-0.09 (-4.23%)
Prev Close
$2.13
Open
$2.04
Day's High
$2.08
Day's Low
$1.94
Volume
38,625
Avg. Vol
24,857
52-wk High
$7.11
52-wk Low
$1.41

CNAT.OQ

Chart for CNAT.OQ

About

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active... (more)

Overall

Beta: --
Market Cap(Mil.): $43.34
Shares Outstanding(Mil.): 21.25
Dividend: --
Yield (%): --

Financials

  CNAT.OQ Industry Sector
P/E (TTM): -- 38.82 34.11
EPS (TTM): -1.28 -- --
ROI: -82.40 -5.72 14.23
ROE: -85.58 -4.83 15.46

BRIEF-Conatus says Louis Lacasse resigned from the board of directors

* Says on June 23, 2016, Louis Lacasse resigned from the board of directors- SEC filing

Jun 24 2016

BRIEF-Conatus extends positive results with emricasan in phase 2 trial

* Conatus extends positive results with Emricasan in Phase 2 liver cirrhosis clinical trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

May 04 2016

Conatus liver drug shows promise in mid-stage trial

Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial.

Jan 05 2016

UPDATE 1-Conatus liver drug shows promise in mid-stage trial

Jan 5 Conatus Pharmaceuticals Inc said its experimental drug reduced the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial.

Jan 05 2016

Conatus liver drug shows positive results in mid-stage trial

Jan 5 Conatus Pharmaceuticals Inc said its experimental drug, emricasan, succeeded in reducing the presence of a protein fragment in patients with liver cirrhosis in a mid-stage trial.

Jan 05 2016

Competitors

  Price Chg
BASF SE (BASFn.DE) €66.59 -0.48
Johnson & Johnson (JNJ.N) $115.63 -1.75
Novartis AG (NOVN.S) CHF75.80 +0.05
Merck & Co., Inc. (MRK.N) $55.88 -1.80
Roche Holding Ltd. (ROG.S) CHF243.40 +2.40
Roche Holding Ltd. (RO.S) CHF247.00 +0.80

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00
Provider : Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.